[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteoarthritis-oa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteoarthritis-oa":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,48,87,109,140,164,191,217,244,273,294,327,351],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100642258","registry-of-outcomes-of-dezawa-musecells-100642258",false,"NCT07645989","Registry of Outcomes of Dezawa MuseCells®","Inclusion Criteria:\n\n1. Received Dezawa MuseCells® as Part of Routine Clinical Care\n2. Patients ( and\u002For authorized representative) capable of providing informed consent and participating in long-term follow-up.\n3. Willingness to Complete Online Survey Assessments\n4. Participants must have reliable access to email or a mobile device and be willing to complete digital surveys at scheduled intervals over a 5-year period.\n5. Diagnosis of a Condition for Which Dezawa MuseCells® Were Administered Includes, but is not limited to, neurologic, musculoskeletal, cardiovascular, immunologic, and systemic degenerative conditions.\n6. Ability to Communicate in the Registry's Supported Language\n7. Participants must be able to read and respond to registry surveys in the designated study language.\n8. Enrollment Within 12 Months of MuseCell® Administration\n\nExclusion Criteria:\n\n1. Not Receive Dezawa MuseCells®-Individuals who have not been treated with Dezawa MuseCells® or received a counterfeit\u002Fnon-licensed product cannot be included.\n2. Unable or Unwilling to Provide Informed Consent Includes individuals with cognitive impairment who lack a legally authorized representative willing to consent on their behalf.\n3. Inability to Participate in Long-Term Digital Follow-Up\n4. Concurrent Participation in an Interventional Clinical Trial Affecting Outcomes\n5. History of Malignancy Diagnosed Within the Past 12 Months\n6. Excludes patients with active or recently treated cancer unless their treating physician determines participation poses no additional safety concerns.\n7. Any Condition That, in the Investigator's Judgment, Would Compromise Data Quality\n8. Use of Non-Licensed or Counterfeit \"Muse-like\" Cells Ensures that registry data reflect outcomes of authentic Dezawa MuseCells® produced under licensed methods.\n9. Pregnant or Actively Breastfeeding at Time of Enrollment","ALL","89 Years",{"count":18,"type":19},5000,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational study is to learn about the long-term effects of Dezawa MuseCells to treat various diseases.\n\nThe Primary Goal: What is the short-term and long- term outcomes of Dezawa Musecells? Participants treated with Dezawa MuseCells as part of their regular medical care and will answer online survey questions about symptoms and clinical outcomes for 5 years.",[24,25,26,27,28],"Osteoarthritis (OA)","Longevity","Wound Care","Pain","Orthopaedic",[30,31,32,33,34],"Muse Cells","stem cells","pain","wound","inflammation","RECRUITING","2026-06-11",{"date":38,"type":39},"2026-06-12","ACTUAL",{"date":41,"type":19},"2026-07-01",{"date":43,"type":19},"2031-12-31",{"name":45,"class":46},"MuseCell Innovations Pte LTD","INDUSTRY",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":15,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":72,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100610737","platelet-rich-plasma-for-musculoskeletal-conditions-100610737","NCT07231471","Platelet Rich Plasma for Musculoskeletal Conditions","PRP for MSK","Inclusion Criteria:\n\n* 18+ years old\n* Musculoskeletal pathology that may benefit from a PRP injection\n* Failed other conservative treatments\n\nExclusion Criteria:\n\n* No active malignancy\n* No active infection in the area of injection\n* No platelet disorder\n* No active systemic infections\n* No patients currently undergoing dialysis",true,"18 Years",{"count":58,"type":19},10000,"INTERVENTIONAL",[61],"NA","The primary purpose of this study is to follow patients with various musculoskeletal (MSK) conditions over a one-year follow-up period after receiving a platelet rich plasma (PRP) injection, assessing changes in their pain levels, functional abilities, and overall patient satisfaction.\n\nThis will develop a robust registry of patients treated with PRP for a range of MSK conditions. These conditions include, but are not limited to, osteoarthritis (OA) of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.",[24,64,65,66,67,68,69,70,71],"Osteoarthritis (OA) of the Knee","Osteoarthritis (OA) of the Hip","Osteoarthritis (OA) of the Shoulder","Osteoarthritis Ankle","Elbow Osteoarthritis","Epicondylitis of the Elbow","Plantar Fasciitis of Both Feet","Tendinopathy",[73,74,75,71],"PRP","Platelet Rich Plasma","Osteoarthritis","2026-05-05",{"date":78,"type":39},"2026-05-06",{"date":80,"type":39},"2025-12-29",{"date":82,"type":19},"2035-01-01",{"name":84,"class":85},"University of Utah","OTHER",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":55,"sex":15,"minAge":56,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":59,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":86},"100636212","empowered-relief-study-100636212","NCT07562750","Empowered Relief Study","Empowered Relief for Osteoarthritis (OA)","Inclusion Criteria:\n\n* Adults age 18 or older who are eligible and interested in enrolling\n\nExclusion Criteria:\n\n* Any records flagged \"break the glass\" or \"research opt out\"",{"count":95,"type":19},100,[61],"\"Empowered Relief\" (ER) Intervention was developed by Beth Darnall, PhD at what is now the Stanford Pain Relief Innovations Lab. Our design is a randomized 3-arm study with test treatment, active control, and placebo arms. Our goals are to provide scientific evidence to demonstrate the efficacy of ER, and also provide a comparison of said efficacy against the standard of care - group pain-CBT. Treatment allocation is randomized to minimize confounder effects. Statisticians performing analyses will be blinded.\n\nThe primary objective of this study is to evaluate the efficacy of Empowered Relief (a novel, single-session (2-hour), evidence-based online pain management class) on reducing pain burden and improving quality of life in patients with advanced osteoarthritis. Empowered Relief is designed to compress key cognitive behavioral therapy (CBT) skills, mindfulness principles, and pain neuroscience education into a brief, scalable format.\n\nSpecifically, the study aims to: Evaluate Clinical Outcomes: Determine whether the intervention reduces pain burden and enhances mobility.\n\nAssess Psychological \\& Behavioral Impact: Examine whether the intervention improves patient-reported understanding of pain, fosters self-efficacy, and increases perceived control, thereby promoting active engagement in their own pain management.\n\nSubject Population: The subject population consists of adult patients diagnosed with advanced osteoarthritis (KL Grade 3-4) who have been deferred from total hip or total knee arthroplasty (THA\u002FTKA). Deferment criteria for this population include existing medical, surgical, behavioral, or personal barriers that currently preclude them from undergoing joint replacement surgery. This population is particularly vulnerable to prolonged suffering, decreased mobility, and compounding psychosocial distress while managing severe somatic pain without immediate surgical options.\n\nMain Research Procedures: The study will utilize a prospective, longitudinal design to measure the impact of the Empowered Relief intervention on the target population.\n\nThe main procedures include: Intervention Delivery: Eligible participants will complete the live Empowered Relief online class (via Zoom) with a certified instructor (Dr. Caryn Lindsey), a 2-hour intervention equipping them with accessible, evidence-based behavioral pain management skills.\n\nData Collection Schedule: Participants will be assessed at three distinct time points: Baseline (pre-intervention), 4-weeks post-treatment, and 8-weeks post-treatment.",[24],"NOT_YET_RECRUITING","2026-04-28",{"date":102,"type":39},"2026-05-01",{"date":104,"type":19},"2026-04-14",{"date":106,"type":19},"2028-04-16",{"name":108,"class":85},"Cedars-Sinai Medical Center",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":59,"phases":119,"briefSummary":120,"conditions":121,"keywords":127,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":86},"100635374","manual-arthroplasty-versus-velys-robotic-assisted-solution-functional-alignment-arthroplasty-for-knee-osteoarthritis-100635374","NCT07551856","Manual Arthroplasty Versus VELYS Robotic-Assisted Solution Functional Alignment Arthroplasty for Knee Osteoarthritis","Manual Arthroplasty Versus VELYS Robotic-Assisted Solution Functional Alignment Arthroplasty for Knee Osteoarthritis (The MARVEL Project): A Pragmatic, Multicentre, Blinded Randomised Controlled Trial With Multi-domain Investigations","MARVEL Project","Inclusion Criteria:\n\n* Aged \\>18 years\n* Primary knee OA\n* Requiring TKA\n* Suitable for either raTKA or mTKA\n* Capable to provide written informed consent\n* Capable and willing to complete outcome measures throughout study period\n\nExclusion Criteria:\n\n* Inflammatory arthritis\n* Significant symptomatic hip, ankle, or contralateral knee OA\n* Prior TKA or major injury or major surgery on the index knee\n* Neuromuscular gait disorders\n* BMI \\>45 kg\u002Fm2\n* Coronal plane deformity \\>15° varus\u002Fvalgus on pre-op HKA radiograph\n* Fixed flexion deformity greater than 15°\n* Bone loss likely to require non-standard implants (e.g. stems, augments)\n* Severe deformity or ligament insufficiency likely to require constraint\n* Inability to comply with the required follow-up assessments or complete PROMs\n* Contraindications to any aspect of the surgical technique",{"count":118,"type":19},346,[61],"The goal of this clinical trial is to learn if the VELYS Robotic-Assisted Solution (VRAS) device helps to improve outcomes from total knee replacement, when compared to regular non-robotic-assisted total knee replacement in the treatment of osteoarthritis. It will also aim to review the longer-term safety and efficiency effects of using this device.\n\nThe main questions it aims to answer are:\n\n1. Does VRAS device-assisted total knee replacement improve patient outcomes (such as their function, satisfaction, and pain) when compared to non-robotic-assisted total knee replacement?\n2. Does VRAS device-assisted total knee replacement improve clinical outcomes (such as revision risk, complications, and hospital length of stay) when compared to non-robotic-assisted total knee replacement?\n3. Does VRAS device-assisted total knee replacement improve functional outcomes (including biomechanical motion analysis) when compared to non-robotic-assisted total knee replacement?\n4. What are the economic and efficiency effects of VRAS device-assisted total knee replacement compared to non-robotic-assisted total knee replacement?\n5. What are the human factor and learning curve effects of introducing VRAS device-assisted total knee replacement into healthcare teams?\n6. Are there any differences in safety and adverse event incidence between VRAS device-assisted total knee replacement and non-robotic-assisted total knee replacement?\n\nParticipants will:\n\n* Be randomised to receive a total knee replacement using either regular non-robotic-assisted methods, or with the use of the VRAS device.\n* Be assessed pre-operatively at the clinic, and then at 6 weeks, 6 months, and 12 months following date of operation. At these appointments patients will answer questionnaires, receive an x-ray (pre-operatively, and at 6 months post-operatively), and a subgroup will be reviewed in the motion analysis laboratory (pre-operatively, and at 6 months post-operatively).\n* Have their longer-term outcomes including any revision operations monitored out to 10 years through national registry data linkage (no actual follow-up for patients after 12 months).",[122,123,124,125,24,75,126],"Knee Osteoarthritis","Osteoarthritis (Knee)","Osteo Arthritis of the Knee","Osteo Arthritis","Osteoarthritis in the Knee",[128,75,129,130],"Knee","Robotic","Alignment",{"date":132,"type":39},"2026-05-04",{"date":134,"type":19},"2026-05-08",{"date":136,"type":19},"2030-05-08",{"name":138,"class":139},"Golden Jubilee National Hospital","OTHER_GOV",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":15,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":151,"conditions":152,"keywords":153,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":86},"100634833","screening-for-biomarkers-of-osteoarthritis-100634833","NCT07544823","Screening for Biomarkers of Osteoarthritis","Screening of Biomarkers for Osteoarthritis and Establishment of a Multidimensional Data Based Early Diagnostic Method","Inclusion Criteria:\n\n1. Aged between 40 and 70 years (inclusive);\n2. Joint pain or stiffness lasting for no less than 3 months;\n3. Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n1. Combined with other severe joint diseases, such as rheumatoid arthritis, gout, etc.;\n2. Suffering from severe systemic diseases, such as heart failure, malignant tumors and others;\n3. Received joint surgery within the past 3 months or taking medications that may affect the progression of osteoarthritis;\n4. Individuals with cognitive dysfunction who are unable to cooperate with the research procedures;\n5. Failure to complete X-ray, MRI examination or follow-up visits as required.","40 Years","70 Years",{"count":150,"type":19},300,"Osteoarthritis (OA) is the most prevalent degenerative joint disease worldwide, which causes pain, loss of joint function and declined quality of life, and ranks as the leading cause of disability among individuals aged over 60 years. In China, the number of patients with osteoarthritis is projected to exceed 200 million by 2044, resulting in a continuously growing demand for medical resources and escalating economic burden.Nevertheless, the lack of effective biomarkers for early diagnosis leads to advanced disease conditions at the time of initial medical consultation and delayed treatment. This project intends to collect blood samples from OA patients and suspected patients in the orthopedic outpatient department of a tertiary hospital. Diagnostic and differential diagnostic tests will be adopted to verify the clinical application value of previously reported candidate biomarkers, so as to screen out biomarkers with favorable validity and reliability. The research findings are expected to provide data support and theoretical basis for the early prevention, early diagnosis and individualized intervention of osteoarthritis.",[24],[75,154],"Biomarker","2026-04-15",{"date":157,"type":39},"2026-04-22",{"date":159,"type":19},"2026-04-20",{"date":161,"type":19},"2026-12-30",{"name":163,"class":85},"The First Affiliated Hospital of Xinxiang Medical College",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":16,"enrollmentInfo":171,"targetDuration":4,"studyType":59,"phases":173,"briefSummary":175,"conditions":176,"keywords":180,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100626011","phase-4-post-operative-pain-relief-zynrelef-or-periarticular-injections-in-ratka-100626011","NCT07430085","Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA","Postoperative Pain Outcomes After Use of Bupivacaine-Meloxicam Extended-Release Solution in Robot Assisted Total Knee Arthroplasty: A Prospective Study","Inclusion Criteria:\n\nMales or females aged 18-89 years\n\nDiagnosed with knee osteoarthritis requiring surgical intervention\n\nIndicated for unilateral RATKA\n\nExclusion Criteria:\n\nPediatric, pregnant, or incarcerated patients\n\nBMI of more than 45 kg\u002Fm2\n\nProlonged opioid use history of \\>5 mg\u002Fday for \\>1 month\n\nHistory of contralateral TKA \\\u003C2 years prior to the index TKA\n\nType 1 Hypersensitivity to NSAIDs or local anesthetics\n\nDiagnosis of severe renal disease",{"count":172,"type":19},150,[174],"PHASE4","Prospective Cohort of patients who are scheduled for a Robot Assisted Total Knee Arthroplasty (RATKA). A prospective survey of patient reported outcome measures (Numeric Rating Scale) will be obtained postoperatively of 72 hours, as well as at the postoperative opioid consumption after 72 hours.",[177,24,64,178,179],"Periarticular Block","Pain After Surgery","Knee Arthroplasty, Total",[181],"Zynrelef","2026-02-24",{"date":184,"type":39},"2026-02-27",{"date":186,"type":19},"2026-01-31",{"date":188,"type":19},"2028-02-28",{"name":190,"class":85},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":15,"minAge":198,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":59,"phases":201,"briefSummary":202,"conditions":203,"keywords":206,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":86},"100626001","impact-of-pre-operative-sarcopenia-on-functional-recovery-after-hip-arthroplasty-in-older-adults-100626001","NCT07429955","Impact of Pre-operative Sarcopenia on Functional Recovery After Hip Arthroplasty in Older Adults","HIP-REGEN","Inclusion Criteria:\n\n\\- Elderly subjects undergoing surgical hip replacement for fracture of the upper end of the femur or severe hip osteoarthritis.\n\nExclusion Criteria for both groups :\n\n* Contraindications to MRI : pacemaker, metallic implants.\n* Presence of a lower-limb prosthesis on the contralateral side to the surgery that may interfere with quadriceps mass measurements.\n* Progressive high-grade neoplasia.\n* Documented major cognitive disorders\n* Under legal protection measures (guardianship, conservatorship, or curatorship).\n* Subjects not affiliated with or not covered by a social security system.\n* Participation in another ongoing study with an active exclusion period.\n\nExclusion criteria - Fracture group :\n\n* Fracture with a suspicion of underlying neoplasia.\n* Placement of a lower-limb prosthesis on the surgical side within the last 12 months.\n* Inability to walk with or without human\u002Ftechnical assistance prior to fracture.\n\nExclusion criteria - Hip osteoarthritis group :\n\n\\- Active inflammatory joint disease (rheumatoid arthritis, spondyloarthritis).","75 Years",{"count":200,"type":19},20,[61],"This single-centre, exploratory study at Montpellier University Hospital will investigate whether having low muscle mass and strength before hip-replacement surgery, a condition called sarcopenia, impact the return to everyday independence in people aged 75 years or older. About 20 volunteers, scheduled for surgery because of a recent femoral-neck fracture or severe arthritis that no longer responds to usual care, will give consent, answer brief health questionnaires, attempt simple walking and chair-rise tests if possible, and provide a small blood sample. While they are already under anaesthesia for their planned operation, the surgical team will take a tiny muscle sample through the same incision, so no extra cuts are needed. During the hospital stay or shortly after discharge, each participant will have a painless MRI scan of the thigh muscles and a very-low-dose bone scan (DXA) to measure muscle and bone health. The research team will then telephone participants at 3 and 6 months to ask about daily activities, walking ability, and any complications. The study lasts about six months for each person and does not alter their usual medical or rehabilitation care. Potential benefits include close follow-up, personalised feedback on muscle and bone results, and helping doctors learn whether pre-surgery muscle weakness predicts slower recovery-information that could guide future, more personalised exercise and nutrition programs. Extra study procedures carry only minimal risks: a routine blood draw, scans with none (MRI) or very little (DXA) radiation, and a muscle biopsy taken during surgery. Taking part is entirely voluntary, and participants may withdraw at any time without affecting their current or future care. The whole project will run for 18 months.",[204,24,205],"Sarcopenia in Elderly","Hip Fracture Surgeries",[204,24,205,207,208],"Functional Recovery","Rehabilitation","2026-02-17",{"date":182,"type":39},{"date":212,"type":19},"2026-02",{"date":214,"type":19},"2027-08",{"name":216,"class":85},"University Hospital, Montpellier",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":55,"sex":15,"minAge":56,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":86},"100615541","ultrasonographic-evaluation-of-talar-cartilage-thickness-in-patients-with-spinal-cord-injury-100615541","NCT07293949","Ultrasonographic Evaluation of Talar Cartilage Thickness in Patients With Spinal Cord Injury","Ultrasonographic Evaluation of Talar Cartilage Thickness in Patients With Spinal Cord Injury: A Cross-Sectional Case-Control Study","Inclusion Criteria:\n\n* Aged between 18 to 60 years,\n* Cervical, thoracal or lumber level of spinal cord injury\n* AIS (American Spinal Injury Association Impairment Scale) Level A, B, C, or D\n* Assisted ambulation of any kind\n* Literacy\n* Giving oral and written consent to participate in the study\n\nExclusion Criteria:\n\n* Patients with sacral level injury\n* AIS E\n* MAS 4 level of spasticity\n* History of any lower extremity operation\n* History of fracture\n* Botulinum toxin injection in the last 6 months\n* Existing diagnosis of any rheumatologic or endocrine diseases","60 Years",{"count":226,"type":19},76,"Spinal cord injury patients often present with musculoskeletal comorbidities, including osteoarthritis. Early detection of cartilage damage is important for preventing osteoarthritis progression. This study aims to compare the talar cartilage thicknesses of spinal cord injury patients with healthy subjects. The secondary aim is to investigate a correlation between the talar cartilage thickness and disease-related parameters. The patient group is to be assessed for talar cartilage thickness (via ultrasound), functional status, spasticity, and ambulation levels.",[229,24],"Spinal Cord Injuries (SCI)",[231,232,233,234],"spinal cord injury","osteoarthritis","musculoskeletal ultrasound","talar cartilage","2026-01-30",{"date":237,"type":39},"2026-02-02",{"date":239,"type":39},"2025-12-20",{"date":241,"type":19},"2026-03-01",{"name":243,"class":139},"Gaziosmanpasa Research and Education Hospital",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":59,"phases":253,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":86},"100617909","the-effectiveness-of-a-herbal-supplement-in-osteoarthritis-100617909","NCT07324746","The Effectiveness of a Herbal Supplement in Osteoarthritis.","Effectiveness of a Herbal Supplement Containing Boswellia Serrata, Curcuma Longa, and Vitis Vinifera in Patients With Osteoarthritis.","Inclusion Criteria:\n\n* Aged ≥ 18\n* Diagnosis of osteoarthritis in knee or hip\n* Numerical Rating Scale (NRS) ≥ 4 during the most painful movement in the last 24 hours\n* Lequesne's Functional Index (LFI) score ≥ 7\n* Ambulant patient\n\nExclusion Criteria:\n\n* Pregnant and breastfeeding\n* Autoimmune disease such as rheumatoid arthritis, gout, lupus\n* Joint trauma, joint injury, joint infection, meniscus tear, complete loss of articular cartilage\n* Expectation of surgery\n* History of the viscous or corticosteroids injections into affected joints or oral corticosteroids within last 12 months\n* Allergy to one of the intervention's ingredients or NSAIDs\n* Peptic ulceration and upper gastrointestinal haemorrhage\n* High alcohol intake, inability to abstain from alcohol, substance abuse, history of addiction\n* Tumor, cancer\n* Abnormal renal or\u002Fand hepatic functions or altered blood chemistry\n* Use of concomitant medication able to interfere with the interventions",{"count":252,"type":19},30,[61],"This study aims to evaluate the effectiveness and safety of a combined herbal supplement containing Boswellia serrata, Curcuma longa, and Vitis vinifera in adults with clinically diagnosed knee or hip osteoarthritis.\n\nThe primary objective is to determine whether the supplement improves osteoarthritis-related symptoms.\n\nThe supplement will be compared with a placebo.\n\nParticipants will:\n\n* take the supplement and placebo for 4 weeks each, one at a time;\n* complete validated questionnaires (6 times online)\n* perform three performance-based physical tests (6 times online)\n* provide a urine sample",[24,65,64,75],[257,258,259,260,75,261,262,263],"Boswellia serrata","Curcuma longa","Curcumin","Turmeric","Grape extract","Knee osteoarthritis","Hip osteoarthritis","2026-01-27",{"date":266,"type":39},"2026-01-29",{"date":268,"type":39},"2025-12-05",{"date":270,"type":19},"2026-09",{"name":272,"class":85},"Middlesex University",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":47},"100617553","does-surgical-treatment-of-cartilage-defects-prevent-osteoarthritis-in-later-life-100617553","NCT07320118","Does Surgical Treatment of Cartilage Defects Prevent Osteoarthritis in Later Life?","Cell Therapy for Osteoarthritis","REACT","Inclusion Criteria:\n\n* ACI patients or patients receiving an alternative treatment\n\nExclusion Criteria:\n\n* Anyone who does not meet the inclusion criteria",{"count":282,"type":19},650,"Observational study to assess the effectiveness of cell therapy for the treatment of osteoarthritis",[24],"2026-01-06",{"date":287,"type":39},"2026-01-08",{"date":289,"type":39},"2010-04-13",{"date":291,"type":19},"2030-01-12",{"name":293,"class":139},"Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":15,"minAge":301,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":59,"phases":305,"briefSummary":307,"conditions":308,"keywords":311,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":4},"100605082","early-phase-1-investigating-the-safety-and-regenerative-potential-of-msc-derived-secretome-combined-with-prgf-in-knee-osteoarthritis-100605082","NCT07157891","Investigating the Safety and Regenerative Potential of MSC-Derived Secretome Combined With PRGF in Knee Osteoarthritis","PRGFSECKOA","Inclusion Criteria:\n\n* Following is the inclusion criteria for the enrolment of patients affected with damaged cartilage in this study:\n\n  * Diagnosed with primary OA in one or both knees based on American College of Rheumatology criteria\n  * Grade I and II Arthritis\n  * Joint pain ≥ 20mm measured by visual analogue scale\n  * Age ranges from 30-55 years of age\n  * BMI 27.12 ± 4.38\n  * Patients with no previous surgical interventions to lower limb\n  * Willing to participate in the study\n\nExclusion Criteria:\n\n* • Secondary OA due to trauma, infection, rheumatoid arthritis, congenital disease or other inflammatory disorders of the knee\n\n  * Diagnosed with a systemic autoimmune disorder, immunodeficiency or coagulation disorder\n  * Had history of malignancy\n  * History of allergy or allergic constitution\n  * Pregnant or breastfeeding women.","30 Years","55 Years",{"count":304,"type":19},25,[306],"EARLY_PHASE1","This Phase I\u002FII randomized clinical trial investigates the safety, feasibility, and early regenerative potential of intra-articular administration of mesenchymal stem cell (MSC)-derived secretome combined with Plasma Rich in Growth Factors (PRGF) in patients with knee osteoarthritis (KOA). The study aims to assess whether this cell-free, biologically enriched therapeutic combination can reduce pain, improve joint function, and promote cartilage repair.",[24,309,310],"Knee Injury","Cartilage Degeneration",[312,313,314,122,315,316,317],"Mesenchymal Stem Cell Secretome","Plasma Rich in Growth Factors (PRGF)","Platelet-Rich Plasma (PRP)","Intra-articular Injection","Cell-free Therapy","Regenerative Medicine","2025-08-28",{"date":320,"type":39},"2025-09-05",{"date":322,"type":19},"2025-12-10",{"date":324,"type":19},"2028-12-11",{"name":326,"class":85},"University of the Punjab",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":337,"conditions":338,"keywords":339,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":86},"100602334","future-osteoarthritis-treatment---free-open-online-course-for-all-100602334","NCT07122154","Future Osteoarthritis Treatment - Free Open Online Course for All","Future Osteoarthritis Treatment (FOOTSTEP) - Free Open Online Course for All","FOOTSTEP","Inclusion Criteria:\n\n* Diagnosed with osteoarthritis by a healthcare professional.\n* Aged 18 years or older.\n* Willing to participate in a series of workshops and provide informed consent\n\nExclusion Criteria:\n\n* Not speaking Swedish",{"count":336,"type":19},50,"The basic treatment for osteoarthritis is education and information, often provided as so-called osteoarthritis schools. These can be provided either physically at the health center or digitally. The content is similar in all osteoarthritis schools. It is not clear whether today's osteoarthritis schools contain what people with osteoarthritis are asking for in terms of education and information. The purpose of this project is therefore to highlight what people with osteoarthritis want the osteoarthritis school to contain and whether there is a need for other ways of running osteoarthritis schools than today.\n\nParticipating in this project means that you will be invited to a focus group with other people who have osteoarthritis. Focus groups will be held at Forum Medicum, Sölvegatan 19 in Lund and will last approximately 1 hour. There will be several different times to choose from. The conversation in the focus group will be recorded.\n\nThe project will collect and register information about you. We will collect information about gender, age, in which joint(s) the person has osteoarthritis and how long they have had osteoarthritis, as well as whether they have participated in any osteoarthritis school and if so, what form (physical or digital). The recorded conversation from the focus group will be transcribed.",[24],[75,340,341],"Self-management","Participatory design","2025-08-07",{"date":344,"type":39},"2025-08-14",{"date":346,"type":19},"2025-10-15",{"date":348,"type":19},"2026-12-31",{"name":350,"class":85},"Eva Ekvall-Hansson",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":55,"sex":15,"minAge":56,"maxAge":4,"enrollmentInfo":357,"targetDuration":358,"studyType":21,"phases":4,"briefSummary":359,"conditions":360,"keywords":363,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":4},"100595761","bone-enhanced-ultrasound-beus-data-library-development-project-100595761","NCT07036653","Bone Enhanced Ultrasound (BEUS) Data Library Development Project","Inclusion Criteria:\n\n* Individuals who have had previous CT or MRI scans of their spine in the past 5 years\n\nExclusion Criteria:\n\n* \\\u003C 18 years old",{"count":95,"type":19},"1 Day","A common treatment for low back pain involves fluoroscopy-guided spinal facet joint injections and\u002For medial branch nerve blocks. Unfortunately, fluoroscopy requires expensive equipment and personnel and exposes patients and healthcare providers to ionizing radiation. Ultrasound offers a safer, lower-cost alternative, but the traditional 2-dimensional (2D) ultrasound systems are limited due to poor image quality, particularly in patients with higher body mass index (BMI).\n\nAs an alternative, a novel Bone Enhanced Ultrasound (BEUS) technology uses artificial intelligence (AI) to create real-time 3-dimensional (3D) images of the spine to guide needle placement for these injections. The AI software is trained by overlaying computed tomography (CT) and ultrasound images from a patient dataset to recognize anatomical landmarks. BEUS aims to ultimately replace fluoroscopy for spinal injections, reducing radiation exposure, lowering healthcare costs, and improving accessibility, especially in rural settings where CT and fluoroscopy are unavailable.\n\nA key limitation, however, is that the current AI system is trained based primarily on patients (mostly pediatric) undergoing perioperative assessment of scoliosis. To address this, the current study aims to develop a new, more clinically relevant training AI dataset by collecting spinal ultrasounds from up to 100 adult participants (most\u002Fall of whom are followed at the local chronic pain clinic for low back pain) with existing spinal CT or magnetic resonance imaging (MRI) scans. This dataset will be used to retrain the current AI model to enhance the accuracy of 3D spinal reconstructions, thereby improving the clinical relevance of the BEUS system.",[361,362,24],"Lower Back Pain","Facet Joint Pain; Low Back Pain",[364,365,366,367],"Facet joint injection","Spine ultrasound","3D ultrasound","Low back pain","2025-07-28",{"date":370,"type":39},"2025-07-29",{"date":372,"type":19},"2025-09-01",{"date":374,"type":19},"2025-12-31",{"name":376,"class":85},"Queen's University"]